Not received warning from USFDA on Clovis: Dishman Pharma

USFDA on Monday had asked for more data on US firm Clovis Oncology Inc's lung cancer drug, Rociletinib, potentially delaying its approval. On back of this news, Dishman Pharma shares took a hit on Tuesday because traders thought Dishman was supplying active ingredient for the drug Rociletinib.JR Vyas, CMD, Dishman Pharma in an interview to CNBC-TV18 clarified that the company had not received any warning from US FDA on Clovis issue.He also stated the company does not factor in revenues from Clovis into their guidance.For the entire interview, watch video